{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:50:24Z","timestamp":1782211824700,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.prro.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:59:19Z","timestamp":1771433959000},"page":"333-337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenalidomide for the Treatment of Chronic Oral Mucositis and Soft Tissue Necrosis After Radiation Therapy"],"prefix":"10.1016","volume":"16","author":[{"given":"Efstathios","family":"Pettas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook-Bin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle N.","family":"Margalit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy B.","family":"Tishler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert I.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel S.","family":"Treister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2026.02.005_bib0001","first-page":"4939","article-title":"A hypothesis for the pathogenesis of radiation-induced oral mucositis: When biological challenges exceed physiologic protective mechanisms. Implications for pharmacological prevention and treatment","volume":"29","author":"Sonis","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.prro.2026.02.005_bib0002","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37265","article-title":"Severe oral mucositis after intensity-modulated radiation therapy for head and neck cancer","volume":"6","author":"Iovoli","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.prro.2026.02.005_bib0003","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1002\/cncr.33100","article-title":"MASCC\/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy","volume":"126","author":"Elad","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.02.005_bib0004","first-page":"4825","article-title":"Chronic oral mucositis after radiotherapy to the head and neck: A new insight","volume":"24","author":"Elad","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.prro.2026.02.005_bib0005","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.ijrobp.2009.02.057","article-title":"Clinical radiation sensitivity with DNA repair disorders: An overview","volume":"74","author":"Pollard","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.02.005_bib0006","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archoto.2011.154","article-title":"Postoperative clinical radiosensitivity in patients with Fanconi anemia and head and neck squamous cell carcinoma","volume":"137","author":"Birkeland","year":"2011","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.prro.2026.02.005_bib0007","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0167-8140(01)00474-1","article-title":"Radiosensitivity in Fanconi's anemia patients","volume":"62","author":"Alter","year":"2002","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.02.005_bib0008","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.ijrobp.2014.04.024","article-title":"Late consequential surgical bed soft tissue necrosis in advanced oropharyngeal squamous cell carcinomas treated with transoral robotic surgery and postoperative radiation therapy","volume":"89","author":"Lukens","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.02.005_bib0009","doi-asserted-by":"crossref","first-page":"e2852","DOI":"10.1097\/MD.0000000000002852","article-title":"Soft tissue necrosis in head and neck cancer patients after transoral robotic surgery or wide excision with primary closure followed by radiation therapy","volume":"95","author":"Lee","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.prro.2026.02.005_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105710","article-title":"Head and neck radiotherapy leading to extensive late oral soft-tissue necrosis","volume":"125","author":"Faustino","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.prro.2026.02.005_bib0011","first-page":"1031","article-title":"Photobiomodulation therapy: Management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patients","volume":"25","author":"Epstein","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.prro.2026.02.005_bib0012","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13014-022-01980-0","article-title":"Irradiation-induced nasopharyngeal necrosis (INN) in newly diagnosed nasopharyngeal carcinoma treated by intensity-modulated radiation therapy: Clinical characteristics and the influence of treatment strategies","volume":"17","author":"Xu","year":"2022","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.02.005_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105180","article-title":"Clinical features of post-radiation nasopharyngeal necrosis and their outcomes following surgical intervention in nasopharyngeal cancer patients","volume":"114","author":"Yang","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.prro.2026.02.005_bib0014","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: An ASTRO clinical practice guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.02.005_bib0015","unstructured":"Revlimid\u00ae (lenalidomide) Capsules [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023."},{"key":"10.1016\/j.prro.2026.02.005_bib0016","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jaad.2013.11.007","article-title":"Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial","volume":"70","author":"Okon","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.prro.2026.02.005_bib0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.prro.2026.02.005_bib0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/RHU.0000000000000100","article-title":"Successful management of refractory pediatric-onset complex aphthosis with lenalidomide","volume":"20","author":"Kalampokis","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.prro.2026.02.005_bib0019","first-page":"197","article-title":"Successful treatment of Behcet's disease with lenalidomide","volume":"158","author":"Green","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.prro.2026.02.005_bib0020","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/ddg.13602","article-title":"Lenalidomide for treatment of recurrent oral aphthae in Adamantiades-Behcet's disease","volume":"16","author":"Ossorio-Garcia","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.prro.2026.02.005_bib0021","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1093\/rheumatology\/kead294","article-title":"Lenalidomide for treatment of refractory aphthosis and neutrophilic pustulosis in familial pyrin-associated autoinflammation with neutrophilic dermatosis","volume":"62","author":"Poujade","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.prro.2026.02.005_bib0022","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.oooo.2023.12.793","article-title":"Thalidomide for management of refractory oral mucosal diseases","volume":"137","author":"Xu","year":"2024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.prro.2026.02.005_bib0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/jop.13259","article-title":"A randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis","volume":"51","author":"Deng","year":"2022","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.prro.2026.02.005_bib0024","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tripleo.2010.03.034","article-title":"A randomized double-blind, positive-control trial of topical thalidomide in erosive oral lichen planus","volume":"110","author":"Wu","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.prro.2026.02.005_bib0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.prro.2026.02.005_bib0026","unstructured":"Thalomid\u00ae (Thalidomide) Capsules [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023."},{"key":"10.1016\/j.prro.2026.02.005_bib0027","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.02.005_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.10.018","article-title":"Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study","volume":"70","author":"Luo","year":"2017","journal-title":"Eur J Cancer"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:33:45Z","timestamp":1782210825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1879850026000548"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2026.02.005","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenalidomide for the Treatment of Chronic Oral Mucositis and Soft Tissue Necrosis After Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}